Trial Outcomes & Findings for Efficacy and Safety Study of SUNPG1623 (NCT NCT02980692)

NCT ID: NCT02980692

Last Updated: 2023-01-27

Results Overview

The American College of Rheumatology20 response measured the percentage of subjects with at least a 20% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein. For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

391 participants

Primary outcome timeframe

week 24

Results posted on

2023-01-27

Participant Flow

Participant milestones

Participant milestones
Measure
SUNPG1623 I
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Placebo
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Double Blind Placebo Controlled Period
STARTED
78
79
77
78
79
Double Blind Placebo Controlled Period
COMPLETED
62
64
60
71
74
Double Blind Placebo Controlled Period
NOT COMPLETED
16
15
17
7
5
Double-blind Follow-up Period
STARTED
62
64
60
71
74
Double-blind Follow-up Period
COMPLETED
62
61
56
67
69
Double-blind Follow-up Period
NOT COMPLETED
0
3
4
4
5

Reasons for withdrawal

Reasons for withdrawal
Measure
SUNPG1623 I
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Placebo
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Double Blind Placebo Controlled Period
Adverse Event
1
2
1
2
0
Double Blind Placebo Controlled Period
Lost to Follow-up
1
0
1
1
0
Double Blind Placebo Controlled Period
Investigator Decision
0
0
0
2
0
Double Blind Placebo Controlled Period
Withdrawal by Subject
2
1
1
2
4
Double Blind Placebo Controlled Period
Protocol Violation
2
0
1
0
0
Double Blind Placebo Controlled Period
Other
1
0
0
0
1
Double Blind Placebo Controlled Period
Failure to show sufficient response to treatment at Week 24
9
12
13
0
0
Double-blind Follow-up Period
Adverse Event
0
0
0
1
1
Double-blind Follow-up Period
Failure to show sufficient response to treatment at Week 24
0
2
1
0
0
Double-blind Follow-up Period
Lost to Follow-up
0
0
1
0
0
Double-blind Follow-up Period
Pregnancy
0
0
1
1
0
Double-blind Follow-up Period
Withdrawal by Subject
0
1
0
1
1
Double-blind Follow-up Period
Other
0
0
1
1
3

Baseline Characteristics

Efficacy and Safety Study of SUNPG1623

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Total
n=391 Participants
Total of all reporting groups
Age, Continuous
50.1 years
STANDARD_DEVIATION 13.28 • n=39 Participants
49.3 years
STANDARD_DEVIATION 11.24 • n=41 Participants
49.2 years
STANDARD_DEVIATION 11.85 • n=35 Participants
47.2 years
STANDARD_DEVIATION 13.35 • n=31 Participants
48.1 years
STANDARD_DEVIATION 13.30 • n=146 Participants
48.8 years
STANDARD_DEVIATION 12.61 • n=19 Participants
Sex: Female, Male
Female
46 Participants
n=39 Participants
37 Participants
n=41 Participants
47 Participants
n=35 Participants
41 Participants
n=31 Participants
44 Participants
n=146 Participants
215 Participants
n=19 Participants
Sex: Female, Male
Male
32 Participants
n=39 Participants
42 Participants
n=41 Participants
30 Participants
n=35 Participants
37 Participants
n=31 Participants
35 Participants
n=146 Participants
176 Participants
n=19 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
12 Participants
n=39 Participants
16 Participants
n=41 Participants
11 Participants
n=35 Participants
9 Participants
n=31 Participants
11 Participants
n=146 Participants
59 Participants
n=19 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
66 Participants
n=39 Participants
63 Participants
n=41 Participants
66 Participants
n=35 Participants
69 Participants
n=31 Participants
68 Participants
n=146 Participants
332 Participants
n=19 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
0 Participants
n=31 Participants
0 Participants
n=146 Participants
0 Participants
n=19 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
0 Participants
n=31 Participants
0 Participants
n=146 Participants
0 Participants
n=19 Participants
Race (NIH/OMB)
Asian
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
0 Participants
n=31 Participants
0 Participants
n=146 Participants
0 Participants
n=19 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
0 Participants
n=31 Participants
0 Participants
n=146 Participants
0 Participants
n=19 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=39 Participants
0 Participants
n=41 Participants
1 Participants
n=35 Participants
1 Participants
n=31 Participants
3 Participants
n=146 Participants
5 Participants
n=19 Participants
Race (NIH/OMB)
White
76 Participants
n=39 Participants
78 Participants
n=41 Participants
75 Participants
n=35 Participants
75 Participants
n=31 Participants
74 Participants
n=146 Participants
378 Participants
n=19 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=39 Participants
0 Participants
n=41 Participants
0 Participants
n=35 Participants
0 Participants
n=31 Participants
0 Participants
n=146 Participants
0 Participants
n=19 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
n=39 Participants
1 Participants
n=41 Participants
1 Participants
n=35 Participants
2 Participants
n=31 Participants
2 Participants
n=146 Participants
8 Participants
n=19 Participants

PRIMARY outcome

Timeframe: week 24

Population: Cochran-Mantel-Haenszel Analysis of ACR20 Response Rate At Week 24 (Missing Response = Non-response) - Primary Analysis (Full Analysis Set)

The American College of Rheumatology20 response measured the percentage of subjects with at least a 20% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein. For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Proportion of Subjects Who Achieve American College of Rheumatology20 Response Rate
0.7949 proportion of subjects
0.7722 proportion of subjects
0.7143 proportion of subjects
0.7308 proportion of subjects
0.5063 proportion of subjects

SECONDARY outcome

Timeframe: week 52

Population: Full Analysis Set

The American College of Rheumatology20 response measured the percentage of subjects with at least a 20% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein. For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=67 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=64 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=60 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=75 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=75 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Proportion of Subjects Who Achieve American College of Rheumatology20 Response Rate
0.9254 proportion of subjects
0.8906 proportion of subjects
0.8667 proportion of subjects
0.8133 proportion of subjects
0.8133 proportion of subjects

SECONDARY outcome

Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and week 52

Population: Cochran-Mantel-Haenszel Analysis of ACR50 Response Rates up to Week 24 Full Analysis Set. ACR50 Response Rates up to Week 52 Full Analysis Set.

The American College of Rheumatology50 response measured the percentage of subjects with at least a 50% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein. For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
Week 1
0 proportion of subjects
0.0253 proportion of subjects
0.0130 proportion of subjects
0.0128 proportion of subjects
0 proportion of subjects
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
Week 4
0.0256 proportion of subjects
0.0506 proportion of subjects
0.0909 proportion of subjects
0.0385 proportion of subjects
0.0253 proportion of subjects
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
Week 8
0.1667 proportion of subjects
0.0759 proportion of subjects
0.1299 proportion of subjects
0.1410 proportion of subjects
0.0759 proportion of subjects
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
Week 12
0.1795 proportion of subjects
0.1772 proportion of subjects
0.2078 proportion of subjects
0.1923 proportion of subjects
0.0633 proportion of subjects
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
Week 16
0.3077 proportion of subjects
0.2785 proportion of subjects
0.2727 proportion of subjects
0.2051 proportion of subjects
0.0506 proportion of subjects
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
Week 20
0.4487 proportion of subjects
0.4177 proportion of subjects
0.2857 proportion of subjects
0.2308 proportion of subjects
0.1646 proportion of subjects
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
Week 24
0.5256 proportion of subjects
0.5063 proportion of subjects
0.4545 proportion of subjects
0.3974 proportion of subjects
0.2405 proportion of subjects
Proportion of Subjects Achieving American College of Rheumatology50 Response Rate
week 52
0.7910 proportion of subjects
0.7500 proportion of subjects
0.7213 proportion of subjects
0.6800 proportion of subjects
0.6267 proportion of subjects

SECONDARY outcome

Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, week 24, and week 52

Population: Cochran-Mantel-Haenszel Analysis of ACR70 Response Rates up to Week 24 Full Analysis Set ACR70 Response Rates up to Week 52 Full Analysis Set.

The American College of Rheumatology70 response measured the percentage of subjects with at least a 50% improvement from Baseline in both tender joints (68) and swollen joints (66) and a 50% improvement in three of the following five criteria: patient global assessment, physician global assessment, patient pain assessment, patient self-assessed disability, and acute-phase C-reactive protein. For 'Units of Measure'- Data entered is proportion of participants, which is calculated by dividing the value obtained (percentage in this case) by 100.

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
Week 1
0 proportion of subjects
0.0127 proportion of subjects
0 proportion of subjects
0 proportion of subjects
0 proportion of subjects
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
Week 4
0.0128 proportion of subjects
0.0127 proportion of subjects
0 proportion of subjects
0.0128 proportion of subjects
0.0127 proportion of subjects
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
Week 8
0.0256 proportion of subjects
0.0380 proportion of subjects
0.0260 proportion of subjects
0.0256 proportion of subjects
0.0380 proportion of subjects
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
Week 12
0.1026 proportion of subjects
0.0380 proportion of subjects
0.0649 proportion of subjects
0.1026 proportion of subjects
0.0127 proportion of subjects
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
Week 16
0.1410 proportion of subjects
0.1266 proportion of subjects
0.1169 proportion of subjects
0.0897 proportion of subjects
0.0253 proportion of subjects
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
Week 20
0.2051 proportion of subjects
0.2658 proportion of subjects
0.1429 proportion of subjects
0.1282 proportion of subjects
0.0380 proportion of subjects
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
Week 24
0.2821 proportion of subjects
0.2911 proportion of subjects
0.2208 proportion of subjects
0.1667 proportion of subjects
0.1013 proportion of subjects
Proportion of Subjects Achieving American College of Rheumatology70 Response Rate
week 52
0.5821 proportion of subjects
0.4844 proportion of subjects
0.3934 proportion of subjects
0.4000 proportion of subjects
0.3733 proportion of subjects

SECONDARY outcome

Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=77 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=78 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=76 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Change From Baseline in Tender Joint Counts
Week 1
-1.5 tender joint counts
Standard Error 0.77
-2.4 tender joint counts
Standard Error 0.76
-2.5 tender joint counts
Standard Error 0.78
-3.1 tender joint counts
Standard Error 0.76
-2.1 tender joint counts
Standard Error 0.76
Change From Baseline in Tender Joint Counts
Week 4
-4.7 tender joint counts
Standard Error 0.89
-4.9 tender joint counts
Standard Error 0.88
-5.4 tender joint counts
Standard Error 0.89
-3.9 tender joint counts
Standard Error 0.88
-4.1 tender joint counts
Standard Error 0.87
Change From Baseline in Tender Joint Counts
Week 8
-7.1 tender joint counts
Standard Error 0.94
-7.8 tender joint counts
Standard Error 0.92
-8.6 tender joint counts
Standard Error 0.94
-7.2 tender joint counts
Standard Error 0.93
-6.9 tender joint counts
Standard Error 0.91
Change From Baseline in Tender Joint Counts
Week 12
-8.3 tender joint counts
Standard Error 0.96
-10.0 tender joint counts
Standard Error 0.94
-8.7 tender joint counts
Standard Error 0.95
-7.8 tender joint counts
Standard Error 0.96
-7.7 tender joint counts
Standard Error 0.94
Change From Baseline in Tender Joint Counts
Week 16
-10.3 tender joint counts
Standard Error 1.04
-11.3 tender joint counts
Standard Error 1.01
-10.7 tender joint counts
Standard Error 1.03
-9.8 tender joint counts
Standard Error 1.04
-8.4 tender joint counts
Standard Error 1.02
Change From Baseline in Tender Joint Counts
Week 20
-11.2 tender joint counts
Standard Error 1.09
-12.3 tender joint counts
Standard Error 1.06
-11.5 tender joint counts
Standard Error 1.07
-11.4 tender joint counts
Standard Error 1.09
-9.9 tender joint counts
Standard Error 1.06
Change From Baseline in Tender Joint Counts
Week 24
-11.9 tender joint counts
Standard Error 1.04
-12.6 tender joint counts
Standard Error 1.01
-12.9 tender joint counts
Standard Error 1.03
-12.0 tender joint counts
Standard Error 1.04
-9.4 tender joint counts
Standard Error 1.02

SECONDARY outcome

Timeframe: Week 52

Population: Full Analysis Set

Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Change From Baseline in Tender Joint Counts
-12.3 tender joint counts
Standard Deviation 11.47
-13.7 tender joint counts
Standard Deviation 11.92
-16.0 tender joint counts
Standard Deviation 12.83
-14.0 tender joint counts
Standard Deviation 10.65
-13.9 tender joint counts
Standard Deviation 12.02

SECONDARY outcome

Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

Population: Statistical Analysis (Mixed Model Repeated Measures) of Change From Baseline in Swollen Joint Counts up to Week 24 - (No Imputation) Full Analysis Set

Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=77 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=78 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=76 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Change From Baseline in Swollen Joint Counts
Week 1
-1.8 Swollen Joint Counts
Standard Error 0.51
-2.1 Swollen Joint Counts
Standard Error 0.51
-1.3 Swollen Joint Counts
Standard Error 0.52
-2.4 Swollen Joint Counts
Standard Error 0.51
-1.3 Swollen Joint Counts
Standard Error 0.51
Change From Baseline in Swollen Joint Counts
Week 4
-4.1 Swollen Joint Counts
Standard Error 0.56
-3.8 Swollen Joint Counts
Standard Error 0.55
-3.8 Swollen Joint Counts
Standard Error 0.56
-3.0 Swollen Joint Counts
Standard Error 0.55
-3.1 Swollen Joint Counts
Standard Error 0.55
Change From Baseline in Swollen Joint Counts
Week 8
-5.8 Swollen Joint Counts
Standard Error 0.55
-5.5 Swollen Joint Counts
Standard Error 0.54
-5.7 Swollen Joint Counts
Standard Error 0.55
-5.0 Swollen Joint Counts
Standard Error 0.55
-4.7 Swollen Joint Counts
Standard Error 0.54
Change From Baseline in Swollen Joint Counts
Week 12
-7.3 Swollen Joint Counts
Standard Error 0.55
-6.6 Swollen Joint Counts
Standard Error 0.54
-6.2 Swollen Joint Counts
Standard Error 0.55
-4.8 Swollen Joint Counts
Standard Error 0.55
-4.9 Swollen Joint Counts
Standard Error 0.54
Change From Baseline in Swollen Joint Counts
Week 16
-8.0 Swollen Joint Counts
Standard Error 0.56
-7.2 Swollen Joint Counts
Standard Error 0.55
-7.0 Swollen Joint Counts
Standard Error 0.55
-6.0 Swollen Joint Counts
Standard Error 0.56
-5.2 Swollen Joint Counts
Standard Error 0.55
Change From Baseline in Swollen Joint Counts
Week 20
-8.3 Swollen Joint Counts
Standard Error 0.56
-7.4 Swollen Joint Counts
Standard Error 0.55
-7.4 Swollen Joint Counts
Standard Error 0.56
-6.8 Swollen Joint Counts
Standard Error 0.56
-6.0 Swollen Joint Counts
Standard Error 0.55
Change From Baseline in Swollen Joint Counts
Week 24
-8.3 Swollen Joint Counts
Standard Error 0.52
-7.7 Swollen Joint Counts
Standard Error 0.51
-8.2 Swollen Joint Counts
Standard Error 0.52
-7.6 Swollen Joint Counts
Standard Error 0.52
-6.5 Swollen Joint Counts
Standard Error 0.51

SECONDARY outcome

Timeframe: Week 52

Population: Full Analysis Set

Peripheral joints were assessed for tenderness and swelling. There is no validated measure to assess peripheral joints in Psoriatic arthritis; the measure used was the American College of Rheumatology joint count initially developed for the assessment of patients with rheumatoid arthritis.

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Change From Baseline in Swollen Joint Counts
-8.7 Swollen Joint Counts
Standard Deviation 6.88
-7.5 Swollen Joint Counts
Standard Deviation 7.07
-9.2 Swollen Joint Counts
Standard Deviation 7.62
-7.5 Swollen Joint Counts
Standard Deviation 5.78
-9.0 Swollen Joint Counts
Standard Deviation 8.80

SECONDARY outcome

Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

100 mm Visual analog scale with descriptors (verbal) : "very good" (0) to "very poor" (100)

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=77 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=78 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=76 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Physician Global Assessment of Disease Activity Visual Analog Scale
Week 1
-7.8 scores on a visual analog scale
Standard Error 1.69
-8.0 scores on a visual analog scale
Standard Error 1.68
-7.2 scores on a visual analog scale
Standard Error 1.70
-6.2 scores on a visual analog scale
Standard Error 1.68
-4.5 scores on a visual analog scale
Standard Error 1.67
Physician Global Assessment of Disease Activity Visual Analog Scale
Week 4
-14.3 scores on a visual analog scale
Standard Error 2.01
-15.7 scores on a visual analog scale
Standard Error 1.99
-15.1 scores on a visual analog scale
Standard Error 1.99
-14.0 scores on a visual analog scale
Standard Error 1.99
-9.7 scores on a visual analog scale
Standard Error 1.95
Physician Global Assessment of Disease Activity Visual Analog Scale
Week 8
-21.9 scores on a visual analog scale
Standard Error 2.20
-23.6 scores on a visual analog scale
Standard Error 2.16
-23.9 scores on a visual analog scale
Standard Error 2.18
-20.8 scores on a visual analog scale
Standard Error 2.18
-16.2 scores on a visual analog scale
Standard Error 2.13
Physician Global Assessment of Disease Activity Visual Analog Scale
Week 12
-27.9 scores on a visual analog scale
Standard Error 2.22
-28.7 scores on a visual analog scale
Standard Error 2.17
-27.6 scores on a visual analog scale
Standard Error 2.19
-23.1 scores on a visual analog scale
Standard Error 2.22
-18.5 scores on a visual analog scale
Standard Error 2.17
Physician Global Assessment of Disease Activity Visual Analog Scale
Week 16
-31.0 scores on a visual analog scale
Standard Error 2.08
-32.1 scores on a visual analog scale
Standard Error 2.03
-31.7 scores on a visual analog scale
Standard Error 2.05
-30.8 scores on a visual analog scale
Standard Error 2.08
-20.2 scores on a visual analog scale
Standard Error 2.04
Physician Global Assessment of Disease Activity Visual Analog Scale
Week 20
-36.7 scores on a visual analog scale
Standard Error 2.19
-36.8 scores on a visual analog scale
Standard Error 2.13
-31.0 scores on a visual analog scale
Standard Error 2.15
-33.0 scores on a visual analog scale
Standard Error 2.19
-24.3 scores on a visual analog scale
Standard Error 2.13
Physician Global Assessment of Disease Activity Visual Analog Scale
Week 24
-36.5 scores on a visual analog scale
Standard Error 2.15
-38.8 scores on a visual analog scale
Standard Error 2.08
-37.5 scores on a visual analog scale
Standard Error 2.11
-36.3 scores on a visual analog scale
Standard Error 2.14
-23.5 scores on a visual analog scale
Standard Error 2.09

SECONDARY outcome

Timeframe: Week 52

Population: Full Analysis Set

100 mm Visual analog scale with descriptors (verbal) : "very good" (0) to "very poor" (100)

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Change From Baseline in Physician Global Assessment of Disease Activity Visual Analog Scale
-40.0 scores on a visual analog scale
Standard Deviation 17.38
-44.3 scores on a visual analog scale
Standard Deviation 19.73
-45.3 scores on a visual analog scale
Standard Deviation 19.84
-42.7 scores on a visual analog scale
Standard Deviation 19.18
-42.0 scores on a visual analog scale
Standard Deviation 20.41

SECONDARY outcome

Timeframe: week 1, week 4, week 8, week 12, week 16, week 20 and week 24

100 mm Visual analog scale descriptors (verbal) : "very well" (0) to "very poorly"(100)

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=77 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=78 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=76 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Patient's Global Assessment of Disease Activity
Week 1
-5.9 scores on a visual analog scale
Standard Error 1.85
-7.5 scores on a visual analog scale
Standard Error 1.84
-6.8 scores on a visual analog scale
Standard Error 1.87
-6.4 scores on a visual analog scale
Standard Error 1.84
-2.8 scores on a visual analog scale
Standard Error 1.84
Patient's Global Assessment of Disease Activity
Week 4
-7.5 scores on a visual analog scale
Standard Error 2.17
-11.9 scores on a visual analog scale
Standard Error 2.14
-9.5 scores on a visual analog scale
Standard Error 2.15
-8.8 scores on a visual analog scale
Standard Error 2.14
-5.9 scores on a visual analog scale
Standard Error 2.11
Patient's Global Assessment of Disease Activity
Week 8
-15.4 scores on a visual analog scale
Standard Error 2.30
-15.5 scores on a visual analog scale
Standard Error 2.25
-14.5 scores on a visual analog scale
Standard Error 2.28
-13.1 scores on a visual analog scale
Standard Error 2.28
-10.1 scores on a visual analog scale
Standard Error 2.23
Patient's Global Assessment of Disease Activity
Week 12
-18.1 scores on a visual analog scale
Standard Error 2.52
-20.3 scores on a visual analog scale
Standard Error 2.46
-16.1 scores on a visual analog scale
Standard Error 2.49
-16.4 scores on a visual analog scale
Standard Error 2.51
-11.2 scores on a visual analog scale
Standard Error 2.46
Patient's Global Assessment of Disease Activity
Week 16
-23.5 scores on a visual analog scale
Standard Error 2.63
-22.0 scores on a visual analog scale
Standard Error 2.57
-18.7 scores on a visual analog scale
Standard Error 2.59
-19.4 scores on a visual analog scale
Standard Error 2.63
-13.8 scores on a visual analog scale
Standard Error 2.58
Patient's Global Assessment of Disease Activity
Week 20
-29.7 scores on a visual analog scale
Standard Error 2.64
-27.3 scores on a visual analog scale
Standard Error 2.57
-22.7 scores on a visual analog scale
Standard Error 2.60
-21.6 scores on a visual analog scale
Standard Error 2.64
-15.6 scores on a visual analog scale
Standard Error 2.58
Patient's Global Assessment of Disease Activity
Week 24
-35.0 scores on a visual analog scale
Standard Error 2.60
-33.3 scores on a visual analog scale
Standard Error 2.52
-33.4 scores on a visual analog scale
Standard Error 2.56
-30.4 scores on a visual analog scale
Standard Error 2.60
-21.7 scores on a visual analog scale
Standard Error 2.54

SECONDARY outcome

Timeframe: Week 52

Population: Full Analysis Set

100 mm Visual analog scale descriptors (verbal) : "very well" (0) to "very poorly"(100)

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Change From Baseline in Patient's Global Assessment of Disease Activity
-42.2 scores on a visual analog scale
Standard Deviation 22.74
-43.8 scores on a visual analog scale
Standard Deviation 24.01
-38.4 scores on a visual analog scale
Standard Deviation 27.90
-37.9 scores on a visual analog scale
Standard Deviation 24.65
-40.5 scores on a visual analog scale
Standard Deviation 28.13

SECONDARY outcome

Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

Population: Statistical Analysis (Mixed Model Repeated Measures) of Change From Baseline in Patient's Pain Assessment up to Week 24 - (No Imputation) Full Analysis Set

100 mm Visual Analog Scale with scale (verbal descriptors) "no pain" (0) to "worst possible pain" (100).

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=77 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=78 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=76 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Patient's Pain Assessment
Week 1
-5.8 scores on a visual analog scale
Standard Error 1.96
-8.1 scores on a visual analog scale
Standard Error 1.95
-5.1 scores on a visual analog scale
Standard Error 1.98
-5.8 scores on a visual analog scale
Standard Error 1.95
-1.6 scores on a visual analog scale
Standard Error 1.95
Patient's Pain Assessment
Week 4
-9.8 scores on a visual analog scale
Standard Error 2.15
-12.8 scores on a visual analog scale
Standard Error 2.12
-8.9 scores on a visual analog scale
Standard Error 2.13
-6.4 scores on a visual analog scale
Standard Error 2.12
-3.9 scores on a visual analog scale
Standard Error 2.09
Patient's Pain Assessment
Week 8
-16.9 scores on a visual analog scale
Standard Error 2.42
-16.1 scores on a visual analog scale
Standard Error 2.37
-16.6 scores on a visual analog scale
Standard Error 2.41
-11.9 scores on a visual analog scale
Standard Error 2.40
-8.5 scores on a visual analog scale
Standard Error 2.35
Patient's Pain Assessment
Week 12
-19.4 scores on a visual analog scale
Standard Error 2.54
-20.4 scores on a visual analog scale
Standard Error 2.48
-15.6 scores on a visual analog scale
Standard Error 2.50
-14.0 scores on a visual analog scale
Standard Error 2.53
-11.5 scores on a visual analog scale
Standard Error 2.48
Patient's Pain Assessment
Week 16
-23.8 scores on a visual analog scale
Standard Error 2.58
-23.2 scores on a visual analog scale
Standard Error 2.52
-20.6 scores on a visual analog scale
Standard Error 2.55
-19.3 scores on a visual analog scale
Standard Error 2.59
-12.8 scores on a visual analog scale
Standard Error 2.54
Patient's Pain Assessment
Week 20
-29.8 scores on a visual analog scale
Standard Error 2.79
-25.3 scores on a visual analog scale
Standard Error 2.71
-21.4 scores on a visual analog scale
Standard Error 2.74
-21.4 scores on a visual analog scale
Standard Error 2.78
-17.1 scores on a visual analog scale
Standard Error 2.72
Patient's Pain Assessment
Week 24
-35.1 scores on a visual analog scale
Standard Error 2.69
-31.6 scores on a visual analog scale
Standard Error 2.60
-32.1 scores on a visual analog scale
Standard Error 2.64
-28.8 scores on a visual analog scale
Standard Error 2.68
-21.5 scores on a visual analog scale
Standard Error 2.63

SECONDARY outcome

Timeframe: Week 52

Population: Full Analysis Set

100 mm Visual Analog Scale with scale (verbal descriptors) "no pain" (0) to "worst possible pain" (100).

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Change From Baseline in Patient's Pain Assessment
-40.7 scores on a visual analog scale
Standard Deviation 21.59
-42.7 scores on a visual analog scale
Standard Deviation 25.67
-38.0 scores on a visual analog scale
Standard Deviation 29.26
-37.6 scores on a visual analog scale
Standard Deviation 26.63
-41.0 scores on a visual analog scale
Standard Deviation 29.83

SECONDARY outcome

Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

eight categories assessed by the Health Assessment Questionnaire - Disability Index 1) dressing and grooming, 2) arising, 3) eating, 4) walking, 5) hygiene, 6) reach, 7) grip and 8) common daily activities was scored as 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty) or 3 (unable to do). The score for the disability index is the mean of the 8 category scores. If more than 2 of the categories, or 25%, are missing, the scale is not scored. If fewer than 2 of the categories are missing, the sum of the categories is divided by the number of answered categories. A higher score indicates greater disability

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=77 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=78 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=76 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Health Assessment Questionnaire- Disability Index
Week 1
-0.0374 score for the disability index
Standard Error 0.03454
-0.0453 score for the disability index
Standard Error 0.03436
-0.0552 score for the disability index
Standard Error 0.03492
-0.0411 score for the disability index
Standard Error 0.03435
-0.0045 score for the disability index
Standard Error 0.03439
Health Assessment Questionnaire- Disability Index
Week 4
-0.0025 score for the disability index
Standard Error 0.04036
-0.0736 score for the disability index
Standard Error 0.03984
-0.0906 score for the disability index
Standard Error 0.03999
-0.0409 score for the disability index
Standard Error 0.03989
-0.0404 score for the disability index
Standard Error 0.03928
Health Assessment Questionnaire- Disability Index
Week 8
-0.1510 score for the disability index
Standard Error 0.04709
-0.1279 score for the disability index
Standard Error 0.04627
-0.2035 score for the disability index
Standard Error 0.04687
-0.1041 score for the disability index
Standard Error 0.04669
-0.1265 score for the disability index
Standard Error 0.04588
Health Assessment Questionnaire- Disability Index
Week 12
-0.1310 score for the disability index
Standard Error 0.04601
-0.2140 score for the disability index
Standard Error 0.04507
-0.2090 score for the disability index
Standard Error 0.04555
-0.1731 score for the disability index
Standard Error 0.04597
-0.1374 score for the disability index
Standard Error 0.04503
Health Assessment Questionnaire- Disability Index
Week 16
-0.2061 score for the disability index
Standard Error 0.04890
-0.2448 score for the disability index
Standard Error 0.04790
-0.2343 score for the disability index
Standard Error 0.04843
-0.2102 score for the disability index
Standard Error 0.04889
-0.1580 score for the disability index
Standard Error 0.04801
Health Assessment Questionnaire- Disability Index
Week 20
-0.3052 score for the disability index
Standard Error 0.05256
-0.2868 score for the disability index
Standard Error 0.05128
-0.2911 score for the disability index
Standard Error 0.05185
-0.1947 score for the disability index
Standard Error 0.05244
-0.2271 score for the disability index
Standard Error 0.05135
Health Assessment Questionnaire- Disability Index
Week 24
-0.3013 score for the disability index
Standard Error 0.05196
-0.3314 score for the disability index
Standard Error 0.05054
-0.3337 score for the disability index
Standard Error 0.05128
-0.2376 score for the disability index
Standard Error 0.05187
-0.1827 score for the disability index
Standard Error 0.05102

SECONDARY outcome

Timeframe: Week 52

Population: Full Analysis Set

eight categories assessed by the Health Assessment Questionnaire - Disability Index 1) dressing and grooming, 2) arising, 3) eating, 4) walking, 5) hygiene, 6) reach, 7) grip and 8) common daily activities was scored as 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty) or 3 (unable to do). The score for the disability index is the mean of the 8 category scores. If more than 2 of the categories, or 25%, are missing, the scale is not scored. If fewer than 2 of the categories are missing, the sum of the categories is divided by the number of answered categories. A higher score indicates greater disability

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Change From Baseline in Health Assessment Questionnaire- Disability Index
-0.4869 score for the disability index
Standard Deviation 0.52093
-0.5430 score for the disability index
Standard Deviation 0.59145
-0.4857 score for the disability index
Standard Deviation 0.56968
-0.4583 score for the disability index
Standard Deviation 0.52285
-0.4700 score for the disability index
Standard Deviation 0.54013

SECONDARY outcome

Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

Population: Statistical Analysis (Mixed Model Repeated Measures) of Change From Baseline in CRP (mg/L) up to Week 24 - (No Imputation) Full Analysis Set

C-reactive protein (CRP) is a blood test marker for inflammation in the body. CRP is produced in the liver and its level is measured by testing the blood. CRP is classified as an acute phase reactant, which means that its levels will rise in response to inflammation

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=77 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=78 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=76 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Acute Phase C - Reactive Protein
Week 1
0.19 mg/L
Standard Error 0.967
-0.75 mg/L
Standard Error 0.961
-0.50 mg/L
Standard Error 0.979
2.08 mg/L
Standard Error 0.961
0.51 mg/L
Standard Error 0.964
Acute Phase C - Reactive Protein
Week 4
-0.71 mg/L
Standard Error 1.239
-3.41 mg/L
Standard Error 1.227
-0.82 mg/L
Standard Error 1.223
0.64 mg/L
Standard Error 1.222
-0.28 mg/L
Standard Error 1.206
Acute Phase C - Reactive Protein
Week 8
-2.96 mg/L
Standard Error 1.506
-3.21 mg/L
Standard Error 1.476
-1.54 mg/L
Standard Error 1.502
1.95 mg/L
Standard Error 1.495
1.24 mg/L
Standard Error 1.465
Acute Phase C - Reactive Protein
Week 12
-2.21 mg/L
Standard Error 1.121
-3.04 mg/L
Standard Error 1.097
-2.59 mg/L
Standard Error 1.104
0.11 mg/L
Standard Error 1.124
1.49 mg/L
Standard Error 1.097
Acute Phase C - Reactive Protein
Week 16
-3.37 mg/L
Standard Error 1.505
-3.57 mg/L
Standard Error 1.462
-1.67 mg/L
Standard Error 1.485
-1.58 mg/L
Standard Error 1.505
2.25 mg/L
Standard Error 1.474
Acute Phase C - Reactive Protein
Week 20
-3.72 mg/L
Standard Error 1.708
-2.76 mg/L
Standard Error 1.656
-2.57 mg/L
Standard Error 1.677
-0.61 mg/L
Standard Error 1.715
4.60 mg/L
Standard Error 1.672
Acute Phase C - Reactive Protein
Week 24
-3.56 mg/L
Standard Error 1.088
-2.33 mg/L
Standard Error 1.054
-3.23 mg/L
Standard Error 1.071
-2.06 mg/L
Standard Error 1.088
0.55 mg/L
Standard Error 1.065

SECONDARY outcome

Timeframe: Week 52

C-reactive protein (CRP) is a blood test marker for inflammation in the body. CRP is produced in the liver and its level is measured by testing the blood. CRP is classified as an acute phase reactant, which means that its levels will rise in response to inflammation. Change from Baseline in C-Reactive Protein.

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Acute Phase C - Reactive Protein
-3.43 mg/L
Standard Deviation 12.506
-3.68 mg/L
Standard Deviation 10.770
-6.05 mg/L
Standard Deviation 19.004
-4.61 mg/L
Standard Deviation 9.508
-6.75 mg/L
Standard Deviation 19.649

SECONDARY outcome

Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, and week 24

Population: Statistical Analysis (Mixed Model Repeated Measures) of Change From Baseline in ESR (mm/hr) up to Week 24 - (No Imputation) Full Analysis Set

An erythrocyte sedimentation rate (ESR) is a type of blood test that measures how quickly erythrocytes (red blood cells) settle at the bottom of a test tube that contains a blood sample. This test help determine if you have a condition that causes inflammation.

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=70 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=68 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=69 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=68 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=62 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Erythrocyte Sedimentation Rate
Week 1
-3.1 mm/hr
Standard Error 1.39
-3.0 mm/hr
Standard Error 1.40
-3.3 mm/hr
Standard Error 1.41
-1.1 mm/hr
Standard Error 1.41
-2.6 mm/hr
Standard Error 1.45
Erythrocyte Sedimentation Rate
Week 4
-6.9 mm/hr
Standard Error 1.46
-5.9 mm/hr
Standard Error 1.48
-5.5 mm/hr
Standard Error 1.45
-5.6 mm/hr
Standard Error 1.47
-4.8 mm/hr
Standard Error 1.51
Erythrocyte Sedimentation Rate
Week 8
-8.7 mm/hr
Standard Error 1.58
-6.5 mm/hr
Standard Error 1.58
-7.1 mm/hr
Standard Error 1.58
-5.5 mm/hr
Standard Error 1.60
-3.6 mm/hr
Standard Error 1.64
Erythrocyte Sedimentation Rate
Week 12
-8.6 mm/hr
Standard Error 1.59
-6.8 mm/hr
Standard Error 1.59
-7.9 mm/hr
Standard Error 1.58
-6.6 mm/hr
Standard Error 1.62
-2.3 mm/hr
Standard Error 1.66
Erythrocyte Sedimentation Rate
Week 16
-9.4 mm/hr
Standard Error 1.93
-8.4 mm/hr
Standard Error 1.92
-8.3 mm/hr
Standard Error 1.91
-6.0 mm/hr
Standard Error 1.96
-3.3 mm/hr
Standard Error 2.02
Erythrocyte Sedimentation Rate
Week 20
-9.6 mm/hr
Standard Error 1.73
-7.2 mm/hr
Standard Error 1.72
-9.2 mm/hr
Standard Error 1.71
-8.5 mm/hr
Standard Error 1.76
-4.4 mm/hr
Standard Error 1.81
Erythrocyte Sedimentation Rate
Week 24
-8.0 mm/hr
Standard Error 1.86
-6.9 mm/hr
Standard Error 1.85
-8.2 mm/hr
Standard Error 1.84
-8.7 mm/hr
Standard Error 1.89
-2.3 mm/hr
Standard Error 1.95

SECONDARY outcome

Timeframe: Week 52

Population: Full Analysis Set

An erythrocyte sedimentation rate (ESR) is a type of blood test that measures how quickly erythrocytes (red blood cells) settle at the bottom of a test tube that contains a blood sample. This test help determine if you have a condition that causes inflammation.

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Change From Baseline in Erythrocyte Sedimentation Rate
-7.2 mm/hr
Standard Deviation 19.58
-7.2 mm/hr
Standard Deviation 15.26
-8.9 mm/hr
Standard Deviation 20.48
-9.7 mm/hr
Standard Deviation 19.02
-9.2 mm/hr
Standard Deviation 20.47

SECONDARY outcome

Timeframe: Week 16

Population: Subjects Who Require Adjustment of Background Therapy at Week 16 Full Analysis Set

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
The Proportion of Subjects Who Require Adjustment of Background Therapy
0 proportion of subjects
0.0127 proportion of subjects
0.0130 proportion of subjects
0.0256 proportion of subjects
0.0127 proportion of subjects

SECONDARY outcome

Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and Week 52

Population: Cochran-Mantel-Haenszel Analysis of DAS28-CRP Response Rates up to Week 24 Full Analysis Set. DAS28-CRP Response Rates up to Week 52-Full Analysis Set

The Disease Activity Score 28-item C-Reactive Protein: assessed across 28 joints including the shoulder, elbow, wrist, MCP (1 through 5), PIP (1 through 5) and knee, with all 14 joints assessed for each side of the body. It is a composite score derived from examination of the 28 joints for swelling and tenderness, global assessment of pain and overall status using a VAS and a blood marker of inflammation (hsCRP). DAS28-CRP(4) = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(CRP+1) + 0.014\*GH + 0.96 TJC- tender joint count, SJC- swollen joint count, CRP- C reactive protein, GH - patient global health

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
Week 12
38.46 percentage of participants
40.51 percentage of participants
31.17 percentage of participants
29.49 percentage of participants
18.99 percentage of participants
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
Week 16
48.72 percentage of participants
48.10 percentage of participants
36.36 percentage of participants
35.90 percentage of participants
13.92 percentage of participants
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
Week 8
35.90 percentage of participants
29.11 percentage of participants
29.87 percentage of participants
23.08 percentage of participants
18.99 percentage of participants
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
Week 20
60.26 percentage of participants
60.76 percentage of participants
37.66 percentage of participants
43.59 percentage of participants
21.52 percentage of participants
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
Week 24
58.97 percentage of participants
64.56 percentage of participants
58.44 percentage of participants
53.85 percentage of participants
30.38 percentage of participants
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
Week 52
85.07 percentage of participants
81.25 percentage of participants
76.27 percentage of participants
71.05 percentage of participants
65.33 percentage of participants
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
Week 1
11.54 percentage of participants
12.66 percentage of participants
10.39 percentage of participants
5.13 percentage of participants
6.33 percentage of participants
Disease Activity Score (DAS) 28 (Joints) C - Reactive Protein (DAS28-CRP) Response Rate
Week 4
20.51 percentage of participants
17.72 percentage of participants
15.58 percentage of participants
15.38 percentage of participants
13.92 percentage of participants

SECONDARY outcome

Timeframe: week 1, week 4, week 8, week 12, week 16, week 20, week 24 and week 52

Population: Cochran-Mantel-Haenszel Analysis of MDA Response Rates up to Week 24 (Missing Response = Non-response) Full Analysis Set. MDA Response Rates up to Week 52- Full Analysis Set

A psoriatic arthritis patient is defined as having a Minimal Disease Activity (MDA) response (Yes/No) when the patient meets at least 5 of the 7 following criteria: 1. tender joint count ≤1; 2. swollen joint count ≤1; 3. PASI score ≤1 or BSA ≤3%; 4. patient Arthritis Pain (VAS) ≤15 mm; 5. patient's global arthritis assessment (VAS) ≤20 mm; 6. HAQ-DI score ≤0.5; 7. tender entheseal points (using LEI) ≤1.

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Minimal Disease Activity
Week 1
0 percentage of participants
1.27 percentage of participants
0 percentage of participants
0 percentage of participants
0 percentage of participants
Minimal Disease Activity
Week 4
3.85 percentage of participants
1.27 percentage of participants
1.30 percentage of participants
2.56 percentage of participants
1.27 percentage of participants
Minimal Disease Activity
Week 8
3.85 percentage of participants
2.53 percentage of participants
2.60 percentage of participants
0 percentage of participants
2.53 percentage of participants
Minimal Disease Activity
Week 12
12.82 percentage of participants
8.86 percentage of participants
7.79 percentage of participants
8.97 percentage of participants
2.53 percentage of participants
Minimal Disease Activity
Week 16
12.82 percentage of participants
6.33 percentage of participants
7.79 percentage of participants
8.97 percentage of participants
1.27 percentage of participants
Minimal Disease Activity
Week 20
17.95 percentage of participants
15.19 percentage of participants
9.09 percentage of participants
8.97 percentage of participants
2.53 percentage of participants
Minimal Disease Activity
Week 24
33.33 percentage of participants
34.18 percentage of participants
28.57 percentage of participants
19.23 percentage of participants
6.33 percentage of participants
Minimal Disease Activity
week 52
56.92 percentage of participants
64.41 percentage of participants
45.00 percentage of participants
47.06 percentage of participants
42.03 percentage of participants

SECONDARY outcome

Timeframe: week 4, week 12, and week 24

Population: Statistical Analysis (Mixed Model Repeated Measures) of Change From Baseline in LDI up to Week 24 - (No Imputation) Full Analysis Set

tenderness score (0 = no tenderness, 1 = tender, 2 = tender and wince, and 3 = tender and withdraw) Total score= {\[Circumference involved digit/ Circumference contralateral Digit (or Tables)\] - 1x 100}x Tenderness score Standard reference: Hands Digit Men Women Thumb 70 58 Index 63 54 Middle 63 54 Ring 59 50 Little 52 44 Standard reference: Feet Digit Men Women Great Toe 82 72 Second 52 46 Middle 50 44 Fourth 50 44 Little 52 45 The difference between circumference of affected finger and contralateral not affected digit cannot be defined for maximum value. Therefore, it is difficult to provide scale range for the final score. No theoretical range exists for the Leeds Dactylitis Index. Lower Leeds Dactylitis Index score represent better outcome.

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=53 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=56 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=46 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=48 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=54 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Change From Baseline in Leeds Dactylitis Index (LDI)
Week 4
-17.385 score on a scale
Standard Error 9.8336
-17.918 score on a scale
Standard Error 9.5818
-19.150 score on a scale
Standard Error 10.4630
-5.385 score on a scale
Standard Error 10.2843
19.891 score on a scale
Standard Error 9.6640
Change From Baseline in Leeds Dactylitis Index (LDI)
Week 12
-21.041 score on a scale
Standard Error 7.8359
-23.163 score on a scale
Standard Error 7.5635
-23.948 score on a scale
Standard Error 8.3579
-9.982 score on a scale
Standard Error 8.2513
-2.990 score on a scale
Standard Error 7.7362
Change From Baseline in Leeds Dactylitis Index (LDI)
Week 24
-22.987 score on a scale
Standard Error 3.5112
-25.123 score on a scale
Standard Error 3.2307
-27.572 score on a scale
Standard Error 3.5088
-19.873 score on a scale
Standard Error 3.4520
-24.706 score on a scale
Standard Error 3.2252

SECONDARY outcome

Timeframe: Week 52

Population: Full Analysis Set

tenderness score (0 = no tenderness, 1 = tender, 2 = tender and wince, and 3 = tender and withdraw) Total score= {\[Circumference involved digit/ Circumference contralateral Digit (or Tables)\] - 1x 100}x Tenderness score Standard reference: Hands Digit Men Women Thumb 70 58 Index 63 54 Middle 63 54 Ring 59 50 Little 52 44 Standard reference: Feet Digit Men Women Great Toe 82 72 Second 52 46 Middle 50 44 Fourth 50 44 Little 52 45 The difference between circumference of affected finger and contralateral not affected digit cannot be defined for maximum value. Therefore, it is difficult to provide scale range for the final score. No theoretical range exists for the Leeds Dactylitis Index. Lower Leeds Dactylitis Index score represent better outcome.

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Change From Baseline in Leeds Dactylitis Index (LDI)
-14.453 score on a scale
Standard Deviation 31.9358
-18.883 score on a scale
Standard Deviation 57.1147
-27.084 score on a scale
Standard Deviation 76.2272
-26.173 score on a scale
Standard Deviation 87.5367
-50.399 score on a scale
Standard Deviation 141.6770

SECONDARY outcome

Timeframe: week 4, week 12 and week 24

Population: Statistical Analysis (Mixed Model Repeated Measures) of Change From Baseline in LEI up to Week 24 - (No Imputation) Full Analysis Set

The LEI examines tenderness at 6 sites: 2 sites (left and right) at each of the lateral epicondyles of the humerus, medial condyles of the femur and the insertion of the Achilles tendon. For each entheseal site, assessment is made of the adjacent joint in terms of tenderness and soft-tissue swelling, with a score of 1 if present. The LEI score range is 0-6. Lower the score better is the outcome

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=72 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=77 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=75 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=76 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=78 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Change From Baseline in Leeds Enthesitis Index (LEI)
Week 4
-0.5 score on a scale
Standard Error 0.15
-0.4 score on a scale
Standard Error 0.14
-0.5 score on a scale
Standard Error 0.14
-0.4 score on a scale
Standard Error 0.14
-0.4 score on a scale
Standard Error 0.14
Change From Baseline in Leeds Enthesitis Index (LEI)
Week 12
-0.8 score on a scale
Standard Error 0.15
-0.7 score on a scale
Standard Error 0.14
-0.9 score on a scale
Standard Error 0.15
-0.8 score on a scale
Standard Error 0.15
-0.7 score on a scale
Standard Error 0.14
Change From Baseline in Leeds Enthesitis Index (LEI)
Week 24
-1.3 score on a scale
Standard Error 0.16
-0.9 score on a scale
Standard Error 0.15
-1.2 score on a scale
Standard Error 0.15
-1.1 score on a scale
Standard Error 0.15
-0.8 score on a scale
Standard Error 0.15

SECONDARY outcome

Timeframe: Week 52

Population: Full Analysis Set

The LEI examines tenderness at 6 sites: 2 sites (left and right) at each of the lateral epicondyles of the humerus, medial condyles of the femur and the insertion of the Achilles tendon. For each entheseal site, assessment is made of the adjacent joint in terms of tenderness and soft-tissue swelling, with a score of 1 if present. The LEI score range is 0-6. Lower the score better is the outcome

Outcome measures

Outcome measures
Measure
SUNPG1623 I
n=78 Participants
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
SUNPG1623 II
n=79 Participants
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose III
n=77 Participants
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
SUNPG1623 Dose IV
n=78 Participants
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Placebo
n=79 Participants
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Change From Baseline in Leeds Enthesitis Index (LEI)
-1.3 score on a scale
Standard Deviation 1.86
-1.0 score on a scale
Standard Deviation 1.56
-1.7 score on a scale
Standard Deviation 2.08
-1.2 score on a scale
Standard Deviation 1.75
-1.2 score on a scale
Standard Deviation 1.82

Adverse Events

Part 1: SUNPG1623 I

Serious events: 2 serious events
Other events: 17 other events
Deaths: 0 deaths

Part 1 : SUNPG1623 II

Serious events: 2 serious events
Other events: 18 other events
Deaths: 0 deaths

Part 1 : SUNPG1623 Dose III

Serious events: 2 serious events
Other events: 16 other events
Deaths: 0 deaths

Part 1 : SUNPG1623 Dose IV

Serious events: 1 serious events
Other events: 22 other events
Deaths: 0 deaths

Part 1 : Placebo

Serious events: 2 serious events
Other events: 18 other events
Deaths: 0 deaths

Part 2: SUNPG1623 I

Serious events: 0 serious events
Other events: 14 other events
Deaths: 0 deaths

Part 2 : SUNPG1623 II

Serious events: 0 serious events
Other events: 11 other events
Deaths: 0 deaths

Part 2 : SUNPG1623 Dose III

Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths

Part 2: Week 24 - 48: SUNPG1623 Dose IV Moved to SUNPG1623 II After Week 24

Serious events: 3 serious events
Other events: 18 other events
Deaths: 0 deaths

Part 2: Week 24 - 48: Placebo Moved to SUNPG1623 II After Week 24

Serious events: 1 serious events
Other events: 9 other events
Deaths: 0 deaths

Part 3: SUNPG1623 I

Serious events: 3 serious events
Other events: 8 other events
Deaths: 1 deaths

Part 3 : SUNPG1623 II

Serious events: 1 serious events
Other events: 1 other events
Deaths: 0 deaths

Part 3 : SUNPG1623 Dose III

Serious events: 1 serious events
Other events: 3 other events
Deaths: 0 deaths

Part 3 :Wash-out Period (SUNPG1623 Dose IV Moved to SUNPG1623 II After Week 24)

Serious events: 1 serious events
Other events: 8 other events
Deaths: 0 deaths

Part 3 : Wash-out Period (Placebo Moved to SUNPG1623 II After Week 24)

Serious events: 2 serious events
Other events: 8 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Part 1: SUNPG1623 I
n=78 participants at risk
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
Part 1 : SUNPG1623 II
n=79 participants at risk
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Part 1 : SUNPG1623 Dose III
n=77 participants at risk
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Part 1 : SUNPG1623 Dose IV
n=78 participants at risk
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Part 1 : Placebo
n=79 participants at risk
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Part 2: SUNPG1623 I
n=78 participants at risk
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
Part 2 : SUNPG1623 II
n=79 participants at risk
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Part 2 : SUNPG1623 Dose III
n=77 participants at risk
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Part 2: Week 24 - 48: SUNPG1623 Dose IV Moved to SUNPG1623 II After Week 24
n=78 participants at risk
Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Part 2: Week 24 - 48: Placebo Moved to SUNPG1623 II After Week 24
n=79 participants at risk
Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Part 3: SUNPG1623 I
n=78 participants at risk
Wash-out period
Part 3 : SUNPG1623 II
n=79 participants at risk
Wash-out period
Part 3 : SUNPG1623 Dose III
n=77 participants at risk
Wash-out period
Part 3 :Wash-out Period (SUNPG1623 Dose IV Moved to SUNPG1623 II After Week 24)
n=78 participants at risk
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks Part 2 : Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48 Part 3 : wash-out period
Part 3 : Wash-out Period (Placebo Moved to SUNPG1623 II After Week 24)
n=79 participants at risk
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks Part 2 : Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48 Part 3 : wash-out period
Cardiac disorders
Angina pectoris
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
1.3%
1/78 • Number of events 1 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Infections and infestations
Chronic tonsillitis
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
1.3%
1/78 • Number of events 1 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Metabolism and nutrition disorders
Hypokalemia
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
1.3%
1/77 • Number of events 1 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Musculoskeletal and connective tissue disorders
Osteoarthritis
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
1.3%
1/77 • Number of events 1 • 72 week
0.00%
0/78 • 72 week
1.3%
1/79 • Number of events 1 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraductal proliferative breast lesion
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
1.3%
1/78 • Number of events 1 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Parathyroid tumour benign
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
1.3%
1/79 • Number of events 1 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Nervous system disorders
Lumbar radiculopathy
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
1.3%
1/78 • Number of events 1 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Nervous system disorders
Syncope
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
1.3%
1/77 • Number of events 1 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Reproductive system and breast disorders
Ovarian cyst
1.3%
1/78 • Number of events 1 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Pregnancy, puerperium and perinatal conditions
Ovarian cyst ruptured
1.3%
1/78 • Number of events 1 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
1.3%
1/79 • Number of events 1 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Vascular disorders
Hypertension
0.00%
0/78 • 72 week
2.5%
2/79 • Number of events 2 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Cardiac disorders
Acute myocardial infarction
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
1.3%
1/79 • Number of events 1 • 72 week
Cardiac disorders
Myocardial infarction
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
1.3%
1/78 • Number of events 1 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
General disorders
Chest pain
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
1.3%
1/78 • Number of events 1 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
General disorders
Multiple organ dysfunction syndrome
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
1.3%
1/79 • Number of events 1 • 72 week
Infections and infestations
Bronchitis
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
1.3%
1/78 • Number of events 1 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Infections and infestations
Pneumonia
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
1.3%
1/78 • Number of events 1 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Injury, poisoning and procedural complications
Ankle fracture
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
1.3%
1/77 • Number of events 1 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Infections and infestations
Toxicity to various agents
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
1.3%
1/78 • Number of events 1 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Nervous system disorders
Multiple sclerosis
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
1.3%
1/79 • Number of events 1 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Pregnancy, puerperium and perinatal conditions
Abortion spontaneous
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
1.3%
1/78 • Number of events 1 • 72 week
0.00%
0/79 • 72 week
Respiratory, thoracic and mediastinal disorders
Dyspnoea
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
1.3%
1/78 • Number of events 1 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Respiratory, thoracic and mediastinal disorders
Pleurisy
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
1.3%
1/78 • Number of events 1 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Respiratory, thoracic and mediastinal disorders
Respiratory failure
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
1.3%
1/78 • Number of events 1 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week

Other adverse events

Other adverse events
Measure
Part 1: SUNPG1623 I
n=78 participants at risk
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
Part 1 : SUNPG1623 II
n=79 participants at risk
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Part 1 : SUNPG1623 Dose III
n=77 participants at risk
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Part 1 : SUNPG1623 Dose IV
n=78 participants at risk
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Part 1 : Placebo
n=79 participants at risk
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Part 2: SUNPG1623 I
n=78 participants at risk
Group: SUNPG1623 I dosage: Short-term dose dosage form: subcutaneous injection frequency of administration: q4 weeks
Part 2 : SUNPG1623 II
n=79 participants at risk
Group: SUNPG1623 II dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Part 2 : SUNPG1623 Dose III
n=77 participants at risk
Group: SUNPG1623 III dosage: Mid-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks
Part 2: Week 24 - 48: SUNPG1623 Dose IV Moved to SUNPG1623 II After Week 24
n=78 participants at risk
Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Part 2: Week 24 - 48: Placebo Moved to SUNPG1623 II After Week 24
n=79 participants at risk
Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48
Part 3: SUNPG1623 I
n=78 participants at risk
Wash-out period
Part 3 : SUNPG1623 II
n=79 participants at risk
Wash-out period
Part 3 : SUNPG1623 Dose III
n=77 participants at risk
Wash-out period
Part 3 :Wash-out Period (SUNPG1623 Dose IV Moved to SUNPG1623 II After Week 24)
n=78 participants at risk
Group: SUNPG1623 IV dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks Part 2 : Subjects who received SUNPG1623 Dose IV during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48 Part 3 : wash-out period
Part 3 : Wash-out Period (Placebo Moved to SUNPG1623 II After Week 24)
n=79 participants at risk
Group: Placebo dosage: Mid to long-term dose dosage form: subcutaneous injection frequency of administration: q12 weeks Part 2 : Subjects who received placebo during Part 1 but failed to show clinical response to treatment at Week 24 entered Part 2 and received SUNPG1623 II until Week 48 Part 3 : wash-out period
Gastrointestinal disorders
Diarrhoea
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
6.4%
5/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
1.3%
1/79 • 72 week
Infections and infestations
Nasopharyngitis
9.0%
7/78 • 72 week
1.3%
1/79 • 72 week
5.2%
4/77 • 72 week
6.4%
5/78 • 72 week
6.3%
5/79 • 72 week
2.6%
2/78 • 72 week
2.5%
2/79 • 72 week
2.6%
2/77 • 72 week
9.0%
7/78 • 72 week
3.8%
3/79 • 72 week
2.6%
2/78 • 72 week
0.00%
0/79 • 72 week
1.3%
1/77 • 72 week
1.3%
1/78 • 72 week
1.3%
1/79 • 72 week
Infections and infestations
Upper respiratory tract infection
2.6%
2/78 • 72 week
5.1%
4/79 • 72 week
3.9%
3/77 • 72 week
3.8%
3/78 • 72 week
1.3%
1/79 • 72 week
3.8%
3/78 • 72 week
5.1%
4/79 • 72 week
2.6%
2/77 • 72 week
5.1%
4/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
1.3%
1/77 • 72 week
2.6%
2/78 • 72 week
0.00%
0/79 • 72 week
Nervous system disorders
Headache
5.1%
4/78 • 72 week
1.3%
1/79 • 72 week
6.5%
5/77 • 72 week
6.4%
5/78 • 72 week
3.8%
3/79 • 72 week
1.3%
1/78 • 72 week
3.8%
3/79 • 72 week
2.6%
2/77 • 72 week
0.00%
0/78 • 72 week
1.3%
1/79 • 72 week
3.8%
3/78 • 72 week
0.00%
0/79 • 72 week
1.3%
1/77 • 72 week
1.3%
1/78 • 72 week
2.5%
2/79 • 72 week
Psychiatric disorders
Sleep Disorder
1.3%
1/78 • 72 week
6.3%
5/79 • 72 week
0.00%
0/77 • 72 week
1.3%
1/78 • 72 week
1.3%
1/79 • 72 week
1.3%
1/78 • 72 week
1.3%
1/79 • 72 week
0.00%
0/77 • 72 week
1.3%
1/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
Vascular disorders
Hypertension
3.8%
3/78 • 72 week
7.6%
6/79 • 72 week
1.3%
1/77 • 72 week
2.6%
2/78 • 72 week
6.3%
5/79 • 72 week
5.1%
4/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
1.3%
1/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
1.3%
1/78 • 72 week
1.3%
1/79 • 72 week
Infections and infestations
Urinary tract infection
0.00%
0/78 • 72 week
1.3%
1/79 • 72 week
3.9%
3/77 • 72 week
1.3%
1/78 • 72 week
3.8%
3/79 • 72 week
1.3%
1/78 • 72 week
1.3%
1/79 • 72 week
0.00%
0/77 • 72 week
5.1%
4/78 • 72 week
1.3%
1/79 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
3.8%
3/78 • 72 week
2.5%
2/79 • 72 week
Investigations
Aspartate aminotransferase increased
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
0.00%
0/79 • 72 week
2.6%
2/78 • 72 week
0.00%
0/79 • 72 week
0.00%
0/77 • 72 week
2.6%
2/78 • 72 week
5.1%
4/79 • 72 week
2.6%
2/78 • 72 week
1.3%
1/79 • 72 week
0.00%
0/77 • 72 week
0.00%
0/78 • 72 week
1.3%
1/79 • 72 week

Additional Information

Head-Clinical Development

Sun Pharma Advanced Research Company Limited

Phone: 912266455645

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place

Restriction type: OTHER